Home ›
Entities
› academia
› 2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib
2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib
Research article (European Journal of Cancer, 2015) · cited 15× · AI/ML
2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib
Summary
2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib is a scholarly article[1].
Key Facts
2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). 2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib. Retrieved May 24, 2026, from https://4ort.xyz/entity/2701-quantification-of-genomic-loss-of-heterozygosity-enables-prospective-selection-of-ovarian-cancer-patients-who-may-d
MLA“2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/2701-quantification-of-genomic-loss-of-heterozygosity-enables-prospective-selection-of-ovarian-cancer-patients-who-may-d.
BibTeX@misc{4ortxyz_2701-quantification-of-genomic-loss-of-heterozygosity-enables-prospective-selection-of-ovarian-cancer-patients-who-may-d_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib}}, year = {2026}, url = {https://4ort.xyz/entity/2701-quantification-of-genomic-loss-of-heterozygosity-enables-prospective-selection-of-ovarian-cancer-patients-who-may-d}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): 2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib — https://4ort.xyz/entity/2701-quantification-of-genomic-loss-of-heterozygosity-enables-prospective-selection-of-ovarian-cancer-patients-who-may-d (retrieved 2026-05-24)
